Lataa...
Anti-chondroitin sulfate proteoglycan 4-specific antibodies modify the effects of vemurafenib on melanoma cells differentially in normoxia and hypoxia
Chondroitin sulfate proteoglycan 4 (CSPG4), a highly immunogenic melanoma tumor antigen, is a potential target for antibody-based immunotherapy. The mechanism by which CSPG4 affects melanoma progression is only partly understood, in particular the involvement of other receptor tyrosine kinases and t...
Tallennettuna:
| Julkaisussa: | Int J Oncol |
|---|---|
| Päätekijät: | , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
D.A. Spandidos
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4485656/ https://ncbi.nlm.nih.gov/pubmed/25997619 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ijo.2015.3010 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|